Interim Chief Executive Officer and Chief Financial Officer
Title: Interim Chief Executive Officer and Chief Financial Officer.
Education: Degree of Bachelor of Science in Accounting and Finance.
Background: Over 20 years of experience in finance. Former CFO at O'Learys Trademark AB. Prior to that, Interim CFO at Rebtel and Head of Business Control at ICA Sverige AB. Before that held leading positions at Scan AB and SkiStar AB. Experience of working in listed-, private equity- and private companies.
Shares in Medivir: 15,000 class B
Warrants in Medivir: 172,500
EVP, Chief Operating Officer
Title: EVP, Chief Operating Officer
Education: Ph. D. in physical chemistry from Royal Institute of Technology and Executive MBA from Stockholm University.
Background: Former CEO of Modus Therapeutics. Prior to that Director, Corporate Development in Sobi. Responsible to build and lead the function Project & Portfolio Management in Biovitrum. Also Member of the Boards of PCI Biotech and Idogen.
Shares in Medivir: 10,000 class B
Warrants in Medivir: 54,630
Interim Chief Medical Officer
Title: Interim Chief Medical Officer
Education: BSc in Physiology from the University of Wales, medical degrees from the University of Wales College of Medicine and Master of Laws degree from Cardiff Law School.
Background: More than 20 years of experience within drug development, mostly in oncology. Previously at Medeval Ltd and more recently at AstraZeneca. He has overseen the clinical development of several global drug programs, interacting with regulatory agencies, external clinical experts and academic groups worldwide. Fellow and Board member of The Faculty of Pharmaceutical Medicine, a former chair of its Ethical Issues committee and a member of its Professional Standards Committee.
Shares in Medivir: 0
Warrants in Medivir: 0
Chief Scientific Officer
Title: Chief Scientific Officer
Education: PhD in Medical Science at Uppsala University
Background: More than 25 years of experience in cancer research. During the last 10 years focused on industrial drug discovery and development projects in oncology. Prior to that he managed an academic research group as principal investigator, and has initiated several innovative scientific projects in cancer biology. He has published more than 50 scientific articles and holds several patents. Adjunct professor at the Medical Faculty of Uppsala University.
Shares in Medivir: 69,172 class B
Warrants in Medivir: 159,010